<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482195</url>
  </required_header>
  <id_info>
    <org_study_id>0916-P</org_study_id>
    <nct_id>NCT01482195</nct_id>
  </id_info>
  <brief_title>Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)</brief_title>
  <official_title>Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fowzan Alkuraya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Khaled Eye Specialist Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King Khaled Eye Specialist Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to assess the safety of gene transfer via subretinal administration of&#xD;
      rAAV2-VMD2-hMERTK in subjects with MERTK-associated retinitis pigmentosa (RP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase I open-label, dose-escalation trial, one eye of each patient (the worse-seeing&#xD;
      eye in five subjects) will receive a submacular injection of the subretinal&#xD;
      rAAV2-VMD2-hMERTK. Patients will be followed daily for 10 days and then at 30, 60, 90, 180,&#xD;
      270, 365, 540, and 730 days post-injection. Data will be collected on (1) full ophthalmologic&#xD;
      examination including best-corrected VA, intraocular pressure, color fundus photographs,&#xD;
      macular spectral-domain optical coherence tomography, and full-field stimulus threshold test&#xD;
      (FST) in both the study and fellow eyes; (2) systemic safety data including CBC, liver, and&#xD;
      kidney function tests, coagulation profiles, urine analysis, AAV antibody titers, peripheral&#xD;
      blood PCR and ASR measurement; and (3) listing of ophthalmological or systemic adverse&#xD;
      effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Ocular Subretinal administration of rAAV2-VMD2-hMERTK .</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic and Ocular Safety</measure>
    <time_frame>2 years</time_frame>
    <description>Detailed history &amp; physical exam were obtained at baseline visit and each post-injection protocol visit searching for systemic adverse events. Included were electrocardiogram, chest X-ray, complete blood count &amp; differential, prothrombin time &amp; INR, partial thromboplastin time, serum electrolytes, full serum chemistries including liver and renal function, urinalysis; serum antibody titers to AAV2 capsid components and antigen-specific reactivity (ASR) assays; blood analysis by DNA PCR to detect vector spread.&#xD;
Ophthalmic safety monitored changes from baseline included 1) corneal abnormalities, afferent pupillary defect, intraocular inflammation, cataract &amp; intraocular pressure changes; 2) retinal changes based on fundus photos; 3) Macular SD-OCT changes in Central macular (CMT) and central foveal thickness (CFT) measurements when patient fixation allowed it, and 4) full field stimulus threshold (FST) to detect any retinal toxicity .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity Measurement</measure>
    <time_frame>2 years and up to 5 years</time_frame>
    <description>Although candidates may have very severe loss of function, an attempt was made to measure a best-corrected visual acuity using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, and measurements were recorded as the number of letters read on each line of the chart (Diabetic Retinopathy Study Research Group 1985). If a patient was unable to read at least three letters of the first line correctly, the chart distance was progressively halved from the standard 4 m until either the first line was correctly read or the shortest distance of 0.5 m was reached. Patients who were unable to read any letters on the chart were tested for light perception and if they perceived light they were assigned the acuity score equivalent of &lt;20/6400. Measurements were performed at baseline and each protocol follow up visit. Improvement in patients who could read was defined as a gain in 5 letters, and in those with those LP vision only to start seeing hand motion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-field Stimulus Threshold Testing (FST).</measure>
    <time_frame>2 years</time_frame>
    <description>Full-field stimulus threshold testing (FST) measures sensitivity of the entire visual field by estimating the lowest luminance of a flash that elicits a visual sensation. The FST measurements were performed at baseline and throughout the protocol visits over two years in the study and fellow eyes, and changes in FST results were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT).</measure>
    <time_frame>2 years</time_frame>
    <description>Central foveal thickness (CFT) measurements were performed at baseline and throughout the protocol visits over two years in the study and fellow eyes (whenever possible), and changes in CFT values were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Macular Thickness (CMT) on Optical Coherence Tomography (OCT).</measure>
    <time_frame>2 years</time_frame>
    <description>Central macular thickness (CMT) measurements were performed at baseline and throughout the protocol visits over two years in the study and fellow eyes (whenever possible), and changes in CMT values were analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Retinal Disease</condition>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Subretinal Injection of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm of 6 patients undergoing subretinal injection of Gene Therapy using rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus. Each patient received the injection in one eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fellow eye without intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>fellow eye without intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus</intervention_name>
    <description>The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.</description>
    <arm_group_label>Subretinal Injection of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MERTK-associated retinal disease;&#xD;
&#xD;
          -  VA: 20/100 or less in worse eye&#xD;
&#xD;
          -  Ability to perform tests of visual and retinal function;&#xD;
&#xD;
          -  Good general health based on a complete physical examination and hematology and&#xD;
             chemistry studies performed at a pre-treatment evaluation;&#xD;
&#xD;
          -  Ability to comply with research procedures;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing eye conditions that would preclude the planned surgery or interfere with&#xD;
             the interpretation of study endpoints or surgical complications (for example,&#xD;
             glaucoma, corneal or lenticular opacities);&#xD;
&#xD;
          -  Complicating systemic diseases (such as medical conditions causing immunosuppression)&#xD;
             that would preclude the gene transfer, ocular surgery or known sensitivity or allergy&#xD;
             to medications planned for use in the peri-operative period;&#xD;
&#xD;
          -  Use of anti-platelet agents that may alter coagulation within 7 days prior to study&#xD;
             agent administration;&#xD;
&#xD;
          -  Use of immunosuppressive medications;&#xD;
&#xD;
          -  Pregnancy or breastfeeding;&#xD;
&#xD;
          -  Individuals (males and females) of childbearing potential who are unwilling to use&#xD;
             effective contraception for 1 year following agent administration and barrier&#xD;
             contraception for 3 months following agent administration;&#xD;
&#xD;
          -  Any other condition that would prevent a subject from completing follow-up&#xD;
             examinations during the course of the study and that, in the opinion of the&#xD;
             investigator, makes the subject unsuitable for the study.&#xD;
&#xD;
          -  Current, or recent (within the past 30 days, or 10 half lives of the drug)&#xD;
             participation, in any other research protocol involving investigational agents or&#xD;
             therapies.&#xD;
&#xD;
          -  Recent (within past 6 months) receipt of an investigational biologic therapeutic&#xD;
             agent.Subjects will not be excluded based on their gender, race or ethnicity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fowzan S Alkuraya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Faisal Specialist Hospital &amp; Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Khaled Eye Specialist Hospital</name>
      <address>
        <city>Riyadh</city>
        <zip>11462</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <results_first_submitted>October 3, 2017</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2021</results_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>King Khaled Eye Specialist Hospital</investigator_affiliation>
    <investigator_full_name>Fowzan Alkuraya</investigator_full_name>
    <investigator_title>Head, Developmental Genetics Unit</investigator_title>
  </responsible_party>
  <keyword>Retinal Disease</keyword>
  <keyword>subretinal gene therapy</keyword>
  <keyword>MERTK</keyword>
  <keyword>retinitis pigmentosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Six eyes of 6 patients were enrolled in this phase of the study. All patients had the typical clinical signs and symptoms of retinitis pigmentosa and tested positive for MERTK mutation. All patients were recruited from the outpatient clinics at King Khaled Eye specialist Hospital (KKESH) starting September 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Recombinant Adeno-Associated Virus</title>
          <description>Recombinant Adeno-Associated Virus: Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>One Year Results</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Recombinant Adeno-Associated Virus</title>
          <description>Recombinant Adeno-Associated Virus: Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" lower_limit="14" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Saudi Arabia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bahrain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systemic and Ocular Safety</title>
        <description>Detailed history &amp; physical exam were obtained at baseline visit and each post-injection protocol visit searching for systemic adverse events. Included were electrocardiogram, chest X-ray, complete blood count &amp; differential, prothrombin time &amp; INR, partial thromboplastin time, serum electrolytes, full serum chemistries including liver and renal function, urinalysis; serum antibody titers to AAV2 capsid components and antigen-specific reactivity (ASR) assays; blood analysis by DNA PCR to detect vector spread.&#xD;
Ophthalmic safety monitored changes from baseline included 1) corneal abnormalities, afferent pupillary defect, intraocular inflammation, cataract &amp; intraocular pressure changes; 2) retinal changes based on fundus photos; 3) Macular SD-OCT changes in Central macular (CMT) and central foveal thickness (CFT) measurements when patient fixation allowed it, and 4) full field stimulus threshold (FST) to detect any retinal toxicity .</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Adeno-Associated Virus Injected Eyes</title>
            <description>Eyes with RP which received a single dose of subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
          <group group_id="O2">
            <title>Fellow Eyes</title>
            <description>Eyes with RP which did not receive subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic and Ocular Safety</title>
          <description>Detailed history &amp; physical exam were obtained at baseline visit and each post-injection protocol visit searching for systemic adverse events. Included were electrocardiogram, chest X-ray, complete blood count &amp; differential, prothrombin time &amp; INR, partial thromboplastin time, serum electrolytes, full serum chemistries including liver and renal function, urinalysis; serum antibody titers to AAV2 capsid components and antigen-specific reactivity (ASR) assays; blood analysis by DNA PCR to detect vector spread.&#xD;
Ophthalmic safety monitored changes from baseline included 1) corneal abnormalities, afferent pupillary defect, intraocular inflammation, cataract &amp; intraocular pressure changes; 2) retinal changes based on fundus photos; 3) Macular SD-OCT changes in Central macular (CMT) and central foveal thickness (CFT) measurements when patient fixation allowed it, and 4) full field stimulus threshold (FST) to detect any retinal toxicity .</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systemic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Afferent pupillary defect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intraocular inflammation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cataract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intraocular pressure changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retinal changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macular thinning on OCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxicity seen on FST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity Measurement</title>
        <description>Although candidates may have very severe loss of function, an attempt was made to measure a best-corrected visual acuity using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, and measurements were recorded as the number of letters read on each line of the chart (Diabetic Retinopathy Study Research Group 1985). If a patient was unable to read at least three letters of the first line correctly, the chart distance was progressively halved from the standard 4 m until either the first line was correctly read or the shortest distance of 0.5 m was reached. Patients who were unable to read any letters on the chart were tested for light perception and if they perceived light they were assigned the acuity score equivalent of &lt;20/6400. Measurements were performed at baseline and each protocol follow up visit. Improvement in patients who could read was defined as a gain in 5 letters, and in those with those LP vision only to start seeing hand motion.</description>
        <time_frame>2 years and up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Adeno-Associated Virus Injected Eyes</title>
            <description>Eyes with RP which received a single dose of subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
          <group group_id="O2">
            <title>Fellow Eyes</title>
            <description>Eyes with RP which did not receive subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity Measurement</title>
          <description>Although candidates may have very severe loss of function, an attempt was made to measure a best-corrected visual acuity using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, and measurements were recorded as the number of letters read on each line of the chart (Diabetic Retinopathy Study Research Group 1985). If a patient was unable to read at least three letters of the first line correctly, the chart distance was progressively halved from the standard 4 m until either the first line was correctly read or the shortest distance of 0.5 m was reached. Patients who were unable to read any letters on the chart were tested for light perception and if they perceived light they were assigned the acuity score equivalent of &lt;20/6400. Measurements were performed at baseline and each protocol follow up visit. Improvement in patients who could read was defined as a gain in 5 letters, and in those with those LP vision only to start seeing hand motion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved VA at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased VA at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable VA at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of VA after 2years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Full-field Stimulus Threshold Testing (FST).</title>
        <description>Full-field stimulus threshold testing (FST) measures sensitivity of the entire visual field by estimating the lowest luminance of a flash that elicits a visual sensation. The FST measurements were performed at baseline and throughout the protocol visits over two years in the study and fellow eyes, and changes in FST results were analyzed.</description>
        <time_frame>2 years</time_frame>
        <population>Six Patients with the clinical diagnosis of RP with a proven MERTK mutation were included. Patients had to be older than 14 years of age and had the viral vector injected into their worse seeing one eye (except case #4).</population>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Adeno-Associated Virus Injected Eyes</title>
            <description>Eyes with RP which received a single dose of subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
          <group group_id="O2">
            <title>Fellow Eyes</title>
            <description>Eyes with RP which did not receive subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Full-field Stimulus Threshold Testing (FST).</title>
          <description>Full-field stimulus threshold testing (FST) measures sensitivity of the entire visual field by estimating the lowest luminance of a flash that elicits a visual sensation. The FST measurements were performed at baseline and throughout the protocol visits over two years in the study and fellow eyes, and changes in FST results were analyzed.</description>
          <population>Six Patients with the clinical diagnosis of RP with a proven MERTK mutation were included. Patients had to be older than 14 years of age and had the viral vector injected into their worse seeing one eye (except case #4).</population>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FST at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.34" lower_limit="-29.65" upper_limit="-17.03"/>
                    <measurement group_id="O2" value="-24.14" lower_limit="-30.40" upper_limit="-17.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FST at 10 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.58" lower_limit="-25.93" upper_limit="-13.23"/>
                    <measurement group_id="O2" value="-20.13" lower_limit="-26.59" upper_limit="-13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FST at 30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.22" lower_limit="-23.98" upper_limit="-14.46"/>
                    <measurement group_id="O2" value="-23.40" lower_limit="-30.60" upper_limit="-16.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FST at 90 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.94" lower_limit="-42.96" upper_limit="15.08"/>
                    <measurement group_id="O2" value="-24.68" lower_limit="-33.54" upper_limit="-15.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FST at 180 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.01" lower_limit="-28.12" upper_limit="-11.90"/>
                    <measurement group_id="O2" value="-22.02" lower_limit="-31.83" upper_limit="-12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FST at 365 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.59" lower_limit="-30.09" upper_limit="-11.08"/>
                    <measurement group_id="O2" value="-22.26" lower_limit="-28.87" upper_limit="-15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FST at 1.5 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.09" lower_limit="-29.04" upper_limit="-13.14"/>
                    <measurement group_id="O2" value="-21.66" lower_limit="-29.81" upper_limit="-13.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FST at 2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.38" lower_limit="-28.54" upper_limit="-12.23"/>
                    <measurement group_id="O2" value="-15.92" lower_limit="-29.78" upper_limit="-2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT).</title>
        <description>Central foveal thickness (CFT) measurements were performed at baseline and throughout the protocol visits over two years in the study and fellow eyes (whenever possible), and changes in CFT values were analyzed.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Adeno-Associated Virus Injected Eyes</title>
            <description>Eyes with RP which received a single dose of subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
          <group group_id="O2">
            <title>Fellow Eyes</title>
            <description>Eyes with RP which did not receive subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT).</title>
          <description>Central foveal thickness (CFT) measurements were performed at baseline and throughout the protocol visits over two years in the study and fellow eyes (whenever possible), and changes in CFT values were analyzed.</description>
          <units>microns.</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CFT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.80" lower_limit="36.69" upper_limit="94.91"/>
                    <measurement group_id="O2" value="74.80" lower_limit="41.22" upper_limit="108.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CFT at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.20" lower_limit="39.89" upper_limit="98.51"/>
                    <measurement group_id="O2" value="75.00" lower_limit="50.51" upper_limit="99.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Macular Thickness (CMT) on Optical Coherence Tomography (OCT).</title>
        <description>Central macular thickness (CMT) measurements were performed at baseline and throughout the protocol visits over two years in the study and fellow eyes (whenever possible), and changes in CMT values were analyzed.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Adeno-Associated Virus Injected Eyes</title>
            <description>Eyes with RP which received a single dose of subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
          <group group_id="O2">
            <title>Fellow Eyes</title>
            <description>Eyes with RP which did not receive subretinal recombinant Adeno-Associated Virus injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Central Macular Thickness (CMT) on Optical Coherence Tomography (OCT).</title>
          <description>Central macular thickness (CMT) measurements were performed at baseline and throughout the protocol visits over two years in the study and fellow eyes (whenever possible), and changes in CMT values were analyzed.</description>
          <units>microns.</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CMT at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.00" lower_limit="65.75" upper_limit="190.25"/>
                    <measurement group_id="O2" value="132.67" lower_limit="40.56" upper_limit="224.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMT at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.33" lower_limit="70.76" upper_limit="193.90"/>
                    <measurement group_id="O2" value="123.76" lower_limit="48.92" upper_limit="198.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study completion, an average of 2 years</time_frame>
      <desc>The adverse events were collected :&#xD;
systematically ( blood samples withdrawn to test for rise in antiViral titers). One temporary rise occurred in the post-operative period in one patient = non serious adverse events)&#xD;
Non systematic collection: ( one patient reported filamentary keratitis, another patient eported oscillopsiain the injected eye- = Other non serious adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Recombinant Adeno-Associated Virus</title>
          <description>Recombinant Adeno-Associated Virus: Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>systemic</sub_title>
                <description>One patient developed a rise in AAV antibodies but with a negative PCR. Serum AAV antibody and antigen specific reactivity measurements for the remaining patients are negative</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Filamentary keratitis</sub_title>
                <description>resolved with postoperative lubrication therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>delayed resolution of subretinal fluid postoperatively, cataract, oscillopsia</sub_title>
                <description>The fluid resolved spontaneously within 6 weeks after surgery with return of vision to baseline.&#xD;
The same patient developed posterior subcapsular cataract and persistent oscillopsia in the operated eye and the cause remains unknown.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fowzan Al Kuraya</name_or_title>
      <organization>King Faisal Specialist Hospital and Research Center</organization>
      <phone>+966 11 442 7875</phone>
      <email>falkuraya@kfshrc.edu.sa</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

